Håkon Sæterøy, Executive Chairman of the Board
Håkon Sæterøy is a Co-founder of IC Targets and has served as Chairman of the Board in 2014 and 2015, then as a Board Member from 2015 to 2017, and again as Chairman since 2017. Håkon is Managing Director of Investor Corporate AS, the second largest shareholder of IC Targets AS. He is a Co-founder and currently serves as CEO of Alzheimer´s diagnostics company Pre Diagnostics AS. Håkon was Executive Chairman of listed diagnostic company DiaGenic ASA from 2002-2010, Executive Chairman of drug development company Serodus ASA from 2008-2012 and chairman/board member of diagnostic company Skannex AS from 2008-2014.
With more than 30 years of experience in management, corporate finance, and business development, Håkon has an extensive international network. He has worked with corporate finance in Norwegian investment banks for 12 years and continued the financing and M&A consultancy business in his own company Investor Corporate AS.
Håkon has been a shareholder and board member in several life science companies in Norway. He was a board member of Nansen Neuroscience Network from 2010-2020 (chairman from 2010-2012) and was a board member of Oslo Cancer Cluster (2007-2014). Håkon holds a Master in Business from the Norwegian School of Economics.
Willy Eidsaunet, Board Member and Chief Medical Officer
Willy Eidsaunet is a Co-founder of IC Targets and has served at the Board of Directors since 2014.
Willy has more than 45 years’ experience within the pharmaceutical and diagnostics industry. He spent 16 years at CIBA-GEIGY in clinical research and as a Medical Director. He joined Nycomed Imaging in 1989 as Head of product management for MRI, was Executive Vice President at Nycomed’s operations in Spain (1992-1994), and Senior Vice President Strategic Marketing/Medical & Regulatory Affairs (1994-1997). After Nycomed’s merger with Amersham plc in 1997 and, later, after General Electric’s acquisition of Nycomed Amersham in 2004, he served as Senior Vice President of Technology Collaboration, R&D (1997-2007).
Willy was the CEO of the life science company IC Contrast up to the merger with Epitarget in 2015. Willy holds a Bachelor in education and languages (German & English) from Norwegian University of Science and Technology and a Bachelor degree in International Management from BI Norwegian Business School.
Tove Flem Jacobsen, Board Member & Chief Commercial Officer
Tove has served as a Board Member since 2019 and has extensive experience in product & clinical development, regulatory approvals, portfolio management and commercialization in the Pharmaceutical Industry sector, whereof 20 years leadership and management experience from Medical Imaging, lately as Global Program Lead for new product innovations in GE HealthCare, Pharmaceutical Diagnostics (PDx). Tove was VP Clinical R&D/ Market Strategy at Clavis Pharma ASA, a publicly listed Biotech, from its early inception to late clinical phase; VP Science and Regulatory Affairs at Aker BioMarine. She has experience from Inven2, Business Development, as a Board member of the Norwegian Cancer Genomics Consortium and has been a member of the Industry Political Committee of LMI, the Norwegian Pharmaceutical Association for several years. Tove holds a Cand. Pharm. (M.Sc. Pharm) from the University of Oslo.
Ståle Charles Kvitle, Board Member
Ståle Charles Kvitle is a Board Member since 2014. Ståle has more than 20 years of experience from Medical Devices within Johnson & Johnson, including leading international roles in sales and marketing for multiple business units, and has extensive experience from product development to commercialization of new technologies. Ståle holds a Master in Business and Economics from BI, Norwegian School of Business.
Jonny Østensen, Board Member and Chief Scientific Officer
Jonny Østensen has more than 30 years’ experience in research, development & innovation within pharmaceutical industry and technology transfer. Jonny was Medical Advisor of Nycomed Imaging, VP Biology of Amersham Health and GE Healthcare (1990-2008) with responsibility for global biology research. In 2008 he joined Inven2 as VP Innovation to assess and commercialize innovative research conducted at the University of Oslo, Oslo University Hospital and the health trusts under the South-Eastern Norway Regional Health Authority. Jonny was Board Director for the Cancer Stem Cell Innovation Center (CAST)-SFI from 2011 to 2015. Jonny is author of 31 peer-reviewed publications and inventor of 55 patent families related to diagnostic imaging technologies. Since 2021, he has been employed by IC Targets as leader for the cardiology project. He was elected as a Board Member in 2024. Jonny holds an MD, PhD from the University of Oslo.